Kura Oncology, Inc. (KURA)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Kura Oncology, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Kura Oncology, Inc. (KURA) has returned -21.75% so far this year and 23.18% over the past 12 months. Over the last ten years, KURA has returned 8.64% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Nov 5, 2015, KURA's average daily return is +0.10%, while the average monthly return is +1.80%. At this rate, your investment would double in approximately 3.2 years.

Historically, 49% of months were positive and 51% were negative. The best month was Sep 2017 with a return of +107.6%, while the worst month was Jan 2016 at -42.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.

On a daily basis, KURA closed higher 48% of trading days. The best single day was Sep 8, 2017 with a return of +72.3%, while the worst single day was Nov 21, 2024 at -36.8%.

Kura Oncology, Inc. has an annualized alpha of 11.03%, beta of 1.10, and R² of 0.08 versus S&P 500 Index. Calculated based on daily prices since November 06, 2015.

• This stock participated in 148.04% of S&P 500 Index downside but only 101.57% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.08 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

KURA ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Kura Oncology, Inc. (KURA) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Kura Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Kura Oncology, Inc. was 86.69%, occurring on Aug 8, 2025. The portfolio has not yet recovered.

The current Kura Oncology, Inc. drawdown is 80.47%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Kura Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Kura Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.